Blue Horizon, a pure play impact investor in the future of food, has invested in Syocin Biotech, a synthetic biology startup focusing on improving food availability and protecting crop production in balance with Nature.
Blue Horizon today announced a Seed portfolio investment in Syocin, a cutting-edge biotechnology company developing high-precision, non-toxic, fully bio-degradable protein-based solutions to protect food crops from bacterial diseases. Blue Horizon co-invested in Syocin with the LATAM biotech fund GRIDX and the European GISEV Family Office, anticipating Syocin’s Seed round that will be opened in the coming months.
Syocin is developing a proprietary Synthetic Biology Platform capable of designing and building high-precision bactericidal proteins to develop each new biobactericide in a significantly accelerated timeline of months, not years.
